Patent: 10,144,763
✉ Email this page to a colleague
Summary for Patent: 10,144,763
Title: | Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) |
Abstract: | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. |
Inventor(s): | Stickel; Juliane (Tubingen, DE), Kowalewski; Daniel Johannes (Tubingen, DE), Rammensee; Hans-Georg (Unterjesingen, DE), Stevanovic; Stefan (Tubingen, DE) |
Assignee: | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) |
Application Number: | 15/965,212 |
Patent Claims: | see list of patent claims |
Details for Patent 10,144,763
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2034-06-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |